ClinicalTrials.gg
CompletedNCT07351968Updated Sep 21, 2026

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

A Phase 1 interventional study of HRS-2129 Tablet and Celecoxib capsule in Moderate Pain in Knee Osteoarthritis and Severe Pain in Knee Osteoarthritis, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Enrollment
32nd of 115
202 · median 100
Started
2026
with 11 others
Phase 1
10 of 136
6 open now
Registered
124th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 32nd largest by enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 10 in phase 1, and was the 124th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.

03

Conditions studied

  • Moderate Pain in Knee Osteoarthritis
  • Severe Pain in Knee Osteoarthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form before starting the activities related to the trial;
  2. The Numerical Evaluation Scale (NRS) pain score of the index knee joint at screening is ≥ 4;
  3. Subjects must be willing to discontinue all medical and non-medical treatments for osteoarthritis pain except rescue medication (acetaminophen) and not use prohibited analgesics throughout the study ;
  4. Male and female subjects of must agree to use highly effective measures with their partners from the signing of the informed consent form until 1 month after the last dose of product.

Exclusion criteria

Exclusion Criteria:

  1. History of other diseases that may involve the target joint;
  2. History of major trauma or surgery of knee joint and hip joint in the past year;
  3. Plan to undergo surgical procedure during the study;
  4. Most or complete loss of mobility;
  5. There are other diseases that may confuse the assessment of osteoarthritis pain;
  6. There is a neuropsychiatric disease, and the investigator's assessment may affect the evaluation of osteoarthritis (OA) or self-score;
  7. There are serious or poorly controlled concomitant diseases;
  8. Those who have a clear history of peptic ulcer, bleeding, perforation or obstruction within 1 year before screening, and have been clinically diagnosed;
  9. Those who require drug treatment or surgical intervention;
  10. History of malignant tumors within 5 years before screening;
  11. Have a history of drug abuse, drug abuse and/or alcoholism within 2 years before screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    HRS-2129 High Dose Group

    HRS-2129 high dose group.

    Drug: HRS-2129 Tablet · Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo

  • Experimental
    HRS-2129 Low Dose Group

    HRS-2129 low dose group.

    Drug: HRS-2129 Tablet · Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo

  • Active comparator
    Celecoxib Group

    Celecoxib group.

    Drug: Celecoxib capsule · Drug: HRS-2129 Tablet Placebo

  • Placebo comparator
    Placebo Group

    Placebo group.

    Drug: Celecoxib Capsule Placebo · Drug: HRS-2129 Tablet Placebo

Interventions

  • HRS-2129 tablet.

  • Celecoxib capsule.

  • DrugCelecoxib Capsule Placebo

    Celecoxib capsule placebo.

  • DrugHRS-2129 Tablet Placebo

    HRS-2129 tablet placebo.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.

    Time frame: At week 4.

Secondary outcomes

  1. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.

    Time frame: From baseline to Week 1, 2 and 3.

  2. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) joint function subscale scores.

    Time frame: From baseline to Week 1, 2, 3 and 4.

  3. Change from baseline in the weekly mean (Week 1, 2, 3 and 4) of the index Knee Numerical Rating Scale (NRS) pain score (resting).

    Time frame: From baseline to Week 1, 2, 3 and 4.

  4. Change from baseline in the weekly mean (Week 1, 2, 3 and 4) of the index Knee Numerical Rating Scale (NRS) pain score (flat walking).

    Time frame: From baseline to Week 1, 2, 3 and 4.

  5. Change from baseline in the overall patient global assessment (PGA) of osteoarthritis condition using the 5-point Likert scale.

    Time frame: From baseline to Week 1, 2, 3 and 4.

  6. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale scores.

    Time frame: From baseline to Week 1, 2, 3 and 4.

  7. Change from baseline in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.

    Time frame: From baseline to Week 1, 2, 3 and 4.

  8. Treatment response: WOMAC pain subscale scores decreased by ≥ 30%, ≥ 50%, ≥ 70% from baseline.

    Time frame: At Week 1, 2, 3 and 4.

  9. Adverse events (AEs) occurred during the study.

    To evaluate the safety and tolerability of HRS-2129 tablets.

    Time frame: During the study, approximately 8 months.

  10. Serious adverse events (SAEs) occurred during the study.

    To evaluate the safety and tolerability of HRS-2129 tablets.

    Time frame: During the study, approximately 8 months.

07

Study locations

1 site
  • Drum Tower Hospital affiliated to Nanjing University School of Medicine
    Nanjing, Jiangsu 210005, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 4 months is below that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 20, 2026
StartActual
Mar 10, 2026
Primary completionActual
Jul 17, 2026
CompletionActual
Jul 17, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351968
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Mar 10, 2026
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2129

Start the discussion